Imago BioSciences Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
41
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.35B
Imago BioSciences General Information
Description
Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).
Contact Information
Website
www.imagobio.comCorporate Office
- 303 Twin Dolphin Drive
- 6th Floor
- Redwood City, CA 94065
- United States
Corporate Office
- 303 Twin Dolphin Drive
- 6th Floor
- Redwood City, CA 94065
- United States
Imago BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 11-Jan-2023 | $1.35B | Completed | Generating Revenue | ||
| 6. PIPE | 09-Jul-2021 | Completed | Generating Revenue | |||
| 5. IPO | 09-Jul-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series C) | 19-Nov-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series B) | 15-Mar-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 22-Feb-2017 | $40.5M | $40.5M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 01-Nov-2016 | Completed | Clinical Trials - Phase 1 |
Imago BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 47,647,051 | $0.000100 | $0.07 | $0.85 | $0.85 | 1x | $0.85 | 22.13% |
Imago BioSciences Comparisons
Industry
Financing
Details
Imago BioSciences Competitors (83)
One of Imago BioSciences’s 83 competitors is Monopar Therapeutics, a Formerly VC-backed company based in Wilmette, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Monopar Therapeutics | Formerly VC-backed | Wilmette, IL | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Elicio Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Aileron Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Imago BioSciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Imago BioSciences Patents
Imago BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4419504-A1 | Kdm1a inhibitors for the treatment of disease | Pending | 18-Oct-2021 | ||
| AU-2021351536-A1 | Pharmaceutical formulations for treating diseases mediated by kdm1a | Pending | 01-Oct-2020 | ||
| CA-3193661-A1 | Pharmaceutical formulations for treating diseases mediated by kdm1a | Pending | 01-Oct-2020 | ||
| EP-4221704-A1 | Pharmaceutical formulations for treating diseases mediated by kdm1a | Pending | 01-Oct-2020 | ||
| US-20230293495-A1 | Pharmaceutical formulations for treating diseases mediated by kdm1a | Pending | 01-Oct-2020 | A61K31/4162 |
Imago BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Imago BioSciences Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Celgene | Corporation | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Farallon Capital Management | Hedge Fund | Minority |
Imago BioSciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
34.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile
Pharmaceuticals
Industry
of 905
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Imago BioSciences FAQs
-
When was Imago BioSciences founded?
Imago BioSciences was founded in 2012.
-
Where is Imago BioSciences headquartered?
Imago BioSciences is headquartered in Redwood City, CA.
-
What is the size of Imago BioSciences?
Imago BioSciences has 41 total employees.
-
What industry is Imago BioSciences in?
Imago BioSciences’s primary industry is Drug Discovery.
-
Is Imago BioSciences a private or public company?
Imago BioSciences is a Private company.
-
What is the current valuation of Imago BioSciences?
The current valuation of Imago BioSciences is .
-
What is Imago BioSciences’s current revenue?
The current revenue for Imago BioSciences is .
-
How much funding has Imago BioSciences raised over time?
Imago BioSciences has raised $315M.
-
Who are Imago BioSciences’s investors?
Amgen Ventures, BlackRock, Celgene, Citadel Enterprise Americas, and Farallon Capital Management are 5 of 18 investors who have invested in Imago BioSciences.
-
Who are Imago BioSciences’s competitors?
Monopar Therapeutics, TScan Therapeutics, Elicio Therapeutics, Aileron Therapeutics, and Kite Pharma are some of the 83 competitors of Imago BioSciences.
-
When was Imago BioSciences acquired?
Imago BioSciences was acquired on 11-Jan-2023.
-
Who acquired Imago BioSciences?
Imago BioSciences was acquired by Merck & Co..
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
